Research Papers:

Efficacy and toxicity of image-guided intensity-modulated radiation therapy combined with dose-escalated brachytherapy for stage IIB cervical cancer

Weiping Wang, Qingyu Meng, Xiaorong Hou, Xin Lian, Junfang Yan, Shuai Sun, Zhikai Liu, Zheng Miao, Dunhuang Wang, Xiaoliang Liu, Ke Hu and Fuquan Zhang _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:102965-102973. https://doi.org/10.18632/oncotarget.22434

Metrics: PDF 1162 views  |   HTML 2297 views  |   ?  


Weiping Wang1,*, Qingyu Meng1,*, Xiaorong Hou1, Xin Lian1, Junfang Yan1, Shuai Sun1, Zhikai Liu1, Zheng Miao1, Dunhuang Wang1, Xiaoliang Liu1, Ke Hu1 and Fuquan Zhang1

1Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China

*These authors contributed equally to this work

Correspondence to:

Ke Hu, email: [email protected]

Fuquan Zhang, email: [email protected]

Keywords: cervical cancer; image-guided radiation therapy; intensity-modulated radiation therapy; dose-escalated brachytherapy; FIGO stage IIB

Received: July 14, 2017     Accepted: October 27, 2017     Published: November 15, 2017


Considering internal organ motion and tumor regression, it is controversial to use intensity-modulated radiation therapy (IMRT) in definitive radiotherapy for cervical cancer. In this study, we evaluated the efficacy and toxicity of IMRT combined with dose-escalated intracavitary brachytherapy (ICBT) for cervical cancer. In total, 373 consecutive FIGO-stage-IIB cervical cancer patients treated with IMRT combined with ICBT and concurrent chemotherapy were included in this study. A dose of 50.4 Gy in 28 fractions was delivered to the pelvis for IMRT. Weekly cone-beam computed tomography or daily megavoltage computed tomography was used for image guiding. For ICBT, 30–36 Gy in five to seven fractions were prescribed to point A. All patients received concurrent chemotherapy. The median follow-up duration was 32.5 months (range, 3.1–119.8 months). The three-year overall survival, disease-free survival and local control rates were 87.5%, 82.2% and 92.5%, respectively. Sixty patients (16.1%) experienced treatment failure, including 23 patients (6.2%) with pelvic relapse. The incidences of ≥grade 3 chronic gastrointestinal and genitourinary toxicity were 2.7% and 2.4%, respectively. These findings indicate that image-guided IMRT combined with dose-escalated ICBT results in good survival with acceptable toxicity in stage IIB cervical cancer patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22434